Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Acalabrutinib plus obinutuzumab shows superior long-term outcomes in treatment-naive chronic lymphocytic leukemia.

Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...

Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...

Improvements seen in overall survival, progression-free survival, and cancer-specific survival. HealthDay News — For patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia ...

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...

Analysis of readmission rates, length of stay and mortality among bone marrow transplant and CAR-T patients in a rural state. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Personalized exercise guidance is needed for people living with Chronic Lymphocytic Leukemia (CLL), the most common type of blood cancer, according to a new study led by the University of Surrey. The ...

"We present the largest study to date describing the racial and ethnic identity of American CLL patients in the era of modern therapies, and the largest study analyzing the general treatment patterns ...